Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Reviews in Clinical and Experimental Pharmacology
  4. Fast Track Articles
  5. Fast Track Article
image of Genetic Determinants of Statin-induced Myopathy: A Network Meta-analysis of Observational Studies

Abstract

Introduction

Statin-induced myopathy (SIM) is a prevalent adverse event impacting treatment adherence. Despite extensive exploration of single nucleotide polymorphisms (SNPs), conflicting evidence obscures their role in SIM incidence, prompting this network meta-analysis.

Methods

Observational studies meeting eligibility criteria (patients on any statin with reported SNPs and SIM details) were systematically reviewed. Severe SIM was defined as creatine kinase elevations exceeding 10 times the upper limit of normal. Mixed treatment comparison pooled estimates were generated from direct and indirect pooled estimates, represented by odds ratios (OR) with 95% confidence intervals (CI), and validated bootstrap analysis.

Results

Thirty-four studies (26,152 participants) examining genotypes spanning drug transporters, metabolizing enzymes, reactive oxygen species production, and myopathy-related genes were analyzed. Significant associations were observed with drug transporters (OR: 1.4; 95% CI: 1.04, 1.5). Notably, solute carrier organic anion transporter 1B1 (SLCO1B1) (rs4149056) exhibited a moderate association with SIM (OR: 2.1; 95% CI: 1.7, 2.6), validated by bootstrap analysis (OR: 2.1; 95% CI: 1.7, 2.8). Similar associations were found for severe SIM with SLCO1B1 (rs4149056) (OR: 3.8; 95% CI: 1.4, 10.4) and ATP Binding Cassette Subfamily B Member 1 (ABCB1) (rs2373588) (OR: 2.8; 95% CI: 1.4, 5.4). Intraclass differences in genetic predictor risks were noted among statins.

Conclusion

Our meta-analysis underscores the significant association of SLCO1B1 with SIM, supporting its clinical utility. Further research is warranted to clarify additional genetic predictors. These findings endorse current guidelines advocating for SLCO1B1 genotyping in statin therapy decisions.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/crcep/10.2174/0127724328356429250315163111
2025-03-28
2025-04-25

  • From This Site

    /content/journals/crcep/10.2174/0127724328356429250315163111
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Matyori A. Brown C.P. Ali A. Sherbeny F. Statins utilization trends and expenditures in the U.S. before and after the implementation of the 2013 ACC/AHA guidelines. Saudi Pharm. J. 2023 31 6 795 800 10.1016/j.jsps.2023.04.002 37228328
    [Google Scholar]
  2. Navar A.M. Peterson E.D. Li S. Robinson J.G. Roger V.L. Goldberg A.C. Virani S. Wilson P.W.F. Nanna M.G. Lee L.V. Elassal J. Wang T.Y. Prevalence and management of symptoms associated with statin therapy in community practice. Circ. Cardiovasc. Qual. Outcomes 2018 11 3 e004249 10.1161/CIRCOUTCOMES.117.004249 29545393
    [Google Scholar]
  3. Abed W. Abujbara M. Batieha A. Ajlouni K. Statin induced myopathy among patients attending the national center for diabetes, endocrinology, & genetics. Ann. Med. Surg. 2022 74 103304 10.1016/j.amsu.2022.103304 35145672
    [Google Scholar]
  4. Blackburn D.F. Dobson R.T. Blackburn J.L. Wilson T.W. Stang M.R. Semchuk W.M. Adherence to statins, beta-blockers and angiotensin-converting enzyme inhibitors following a first cardiovascular event: A retrospective cohort study. Can. J. Cardiol. 2005 21 6 485 488 15917876
    [Google Scholar]
  5. Chowdhury R. Khan H. Heydon E. Shroufi A. Fahimi S. Moore C. Stricker B. Mendis S. Hofman A. Mant J. Franco O.H. Adherence to cardiovascular therapy: A meta-analysis of prevalence and clinical consequences. Eur. Heart J. 2013 34 38 2940 2948 10.1093/eurheartj/eht295 23907142
    [Google Scholar]
  6. Camerino G.M. Tarantino N. Canfora I. De Bellis M. Musumeci O. Pierno S. Statin-induced myopathy: Translational studies from preclinical to clinical evidence. Int. J. Mol. Sci. 2021 22 4 2070 10.3390/ijms22042070 33669797
    [Google Scholar]
  7. Hopewell J.C. Offer A. Haynes R. Bowman L. Li J. Chen F. Bulbulia R. Lathrop M. Baigent C. Landray M.J. Collins R. Armitage J. Parish S. Independent risk factors for simvastatin-related myopathy and relevance to different types of muscle symptom. Eur. Heart J. 2020 41 35 3336 3342 10.1093/eurheartj/ehaa574 32702748
    [Google Scholar]
  8. Kee P.S. Chin P.K.L. Kennedy M.A. Maggo S.D.S. Pharmacogenetics of statin-induced myotoxicity. Front. Genet. 2020 11 575678 10.3389/fgene.2020.575678 33193687
    [Google Scholar]
  9. Hou Q. Li S. Li L. Li Y. Sun X. Tian H. Association between SLCO1B1 gene T521C polymorphism and statin-related myopathy risk. Medicine 2015 94 37 e1268 10.1097/MD.0000000000001268 26376374
    [Google Scholar]
  10. Xiang Q. Chen S. Ma L. Hu K. Zhang Z. Mu G. Xie Q. Zhang X. Cui Y. Association between SLCO1B1 T521C polymorphism and risk of statin-induced myopathy: A meta-analysis. Pharmacogenomics J. 2018 18 6 721 729 10.1038/s41397‑018‑0054‑0 30250148
    [Google Scholar]
  11. Yee J. Kim H. Heo Y. Yoon H.Y. Song G. Gwak H.S. Association between CYP3A5 polymorphism and statin-induced adverse events: A systemic review and meta-analysis. J. Pers. Med. 2021 11 7 677 10.3390/jpm11070677 34357144
    [Google Scholar]
  12. Liu M. Fan F. Zhang Y. Li J. The association of GATM polymorphism with statin-induced myopathy: A systematic review and meta-analysis. Eur. J. Clin. Pharmacol. 2021 77 3 349 357 10.1007/s00228‑020‑03019‑3 33051696
    [Google Scholar]
  13. Vassy J.L. Gaziano J.M. Green R.C. Ferguson R.E. Advani S. Miller S.J. Chun S. Hage A.K. Seo S.J. Majahalme N. MacMullen L. Zimolzak A.J. Brunette C.A. Effect of pharmacogenetic testing for statin myopathy risk vs usual care on blood cholesterol. JAMA Netw. Open 2020 3 12 e2027092 10.1001/jamanetworkopen.2020.27092 33270123
    [Google Scholar]
  14. Peyser B. Perry E.P. Singh K. Gill R.D. Mehan M.R. Haga S.B. Musty M.D. Milazzo N.A. Savard D. Li Y.J. Trujilio G. Voora D. Effects of delivering SLCO1B1 pharmacogenetic information in randomized trial and observational settings. Circ. Genom. Precis. Med. 2018 11 9 e002228 10.1161/CIRCGEN.118.002228 30354330
    [Google Scholar]
  15. a Agarwal A. Rochwerg B. Sevransky J.E. 21st century evidence: Randomized controlled trials versus systematic reviews and meta-analyses. Crit. Care Med. 2021 49 12 2001 2002 10.1097/CCM.0000000000005343 34582418
    [Google Scholar]
  16. a Agarwal A. Rochwerg B. Sevransky J.E. 21st century evidence: Randomized controlled trials versus systematic reviews and meta-analyses. Crit. Care Med. 2021 49 12 2001 2002 10.1097/CCM.0000000000005343 34582418
    [Google Scholar]
  17. Hutton B. Salanti G. Caldwell D.M. Chaimani A. Schmid C.H. Cameron C. Ioannidis J.P.A. Straus S. Thorlund K. Jansen J.P. Mulrow C. Catalá-López F. Gøtzsche P.C. Dickersin K. Boutron I. Altman D.G. Moher D. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: Checklist and explanations. Ann. Intern. Med. 2015 162 11 777 784 10.7326/M14‑2385 26030634
    [Google Scholar]
  18. Gierisch J.M. Beadles C. Shapiro A. Health Disparities in Quality Indicators of Healthcare Among Adults with Mental Illness Department of Veterans Affairs Washington (DC) (US)
    [Google Scholar]
  19. Higgins J.P.T. Thompson S.G. Quantifying heterogeneity in a meta‐analysis. Stat. Med. 2002 21 11 1539 1558 10.1002/sim.1186 12111919
    [Google Scholar]
  20. EpiGear International 2024 Available from: https://www.epigear.com/index.htm
  21. Introduction to GRADE handbook. 2024 Available from: https://gdt.gradepro.org/app/handbook/handbook.html
  22. Statin equivalent dose. 2024 Available from: https://globalrph.com/drugs/statins-hmg-coa-reductase-inhibitors/ Available from: https://renaissance.stonybrookmedicine.edu/pharmacy-informatics/calculators/statin-equivalent-doses
  23. Wallace B.C. Lajeunesse M.J. Dietz G. Dahabreh I.J. Trikalinos T.A. Schmid C.H. Gurevitch J. Open MEE : Intuitive, open‐source software for meta‐analysis in ecology and evolutionary biology. Methods Ecol. Evol. 2017 8 8 941 947 10.1111/2041‑210X.12708
    [Google Scholar]
  24. Alghalyini B. El Shamieh S. Salami A. V Siest S. Fakhoury H.M. Fakhoury R. Effect of SLCO1B1 gene polymorphisms and vitamin D on statin-induced myopathy. Drug Metab. Pers. Ther. 2018 33 1 41 47 10.1515/dmpt‑2017‑0030 29420305
    [Google Scholar]
  25. Bai X. Zhang B. Wang P. Wang G. Li J. Wen D. Long X. Sun H. Liu Y. Huang M. Zhong S. Effects of SLCO1B1 and GATM gene variants on rosuvastatin-induced myopathy are unrelated to high plasma exposure of rosuvastatin and its metabolites. Acta Pharmacol. Sin. 2019 40 4 492 499 10.1038/s41401‑018‑0013‑y 29950617
    [Google Scholar]
  26. Bakar N.S. Neely D. Avery P. Brown C. Daly A.K. Kamali F. Genetic and clinical factors are associated with statin‐related myotoxicity of moderate severity: A case–control study. Clin. Pharmacol. Ther. 2018 104 1 178 187 10.1002/cpt.887 28940218
    [Google Scholar]
  27. Brunham L.R. Lansberg P.J. Zhang L. Miao F. Carter C. Hovingh G.K. Visscher H. Jukema J.W. Stalenhoef A.F. Ross C.J.D. Carleton B.C. Kastelein J.J.P. Hayden M.R. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. Pharmacogenomics J. 2012 12 3 233 237 10.1038/tpj.2010.92 21243006
    [Google Scholar]
  28. Carr D.F. O’Meara H. Jorgensen A.L. Campbell J. Hobbs M. McCann G. van Staa T. Pirmohamed M. SLCO1B1 genetic variant associated with statin-induced myopathy: A proof-of-concept study using the clinical practice research datalink. Clin. Pharmacol. Ther. 2013 94 6 695 701 10.1038/clpt.2013.161 23942138
    [Google Scholar]
  29. Carr D.F. Alfirevic A. Johnson R. Chinoy H. van Staa T. Pirmohamed M. GATM gene variants and statin myopathy risk. Nature 2014 513 7518 E1 10.1038/nature13628 25230669
    [Google Scholar]
  30. Ferrari M. Guasti L. Maresca A. Mirabile M. Contini S. Grandi A.M. Marino F. Cosentino M. Association between statin-induced creatine kinase elevation and genetic polymorphisms in SLCO1B1, ABCB1 and ABCG2. Eur. J. Clin. Pharmacol. 2014 70 5 539 547 10.1007/s00228‑014‑1661‑6 24595600
    [Google Scholar]
  31. Fiegenbaum M. Dasilveira F. Vandersand C. Vandersand L. Ferreira M. Pires R. Hutz M. The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment. Clin. Pharmacol. Ther. 2005 78 5 551 558 10.1016/j.clpt.2005.08.003 16321621
    [Google Scholar]
  32. Floyd J.S. Bis J.C. Brody J.A. Heckbert S.R. Rice K. Psaty B.M. GATM locus does not replicate in rhabdomyolysis study. Nature 2014 513 7518 E1 E3 10.1038/nature13629 25230668
    [Google Scholar]
  33. Frudakis T.N. Thomas M.J. Ginjupalli S.N. Handelin B. Gabriel R. Gomez H.J. CYP2D6*4 polymorphism is associated with statin-induced muscle effects. Pharmacogenet. Genomics 2007 17 9 695 707 10.1097/FPC.0b013e328012d0a9 17700359
    [Google Scholar]
  34. Hoenig M.R. Walker P.J. Gurnsey C. Beadle K. Johnson L. The C3435T polymorphism in ABCB1 influences atorvastatin efficacy and muscle symptoms in a high-risk vascular cohort. J. Clin. Lipidol. 2011 5 2 91 96 10.1016/j.jacl.2011.01.001 21392722
    [Google Scholar]
  35. Vrablík M. Dlouhá D. Adámková V. Zlatohlavek L. Viklický O. Hrubá P. Češka R. Vrablík M. SLCO1B1 polymorphism is not associated with risk of statin-induced myalgia/myopathy in a Czech population. Med. Sci. Monit. 2015 21 1454 1459 10.12659/MSM.893007 25992810
    [Google Scholar]
  36. Hubacek J.A. Adamkova V. Zlatohlavek L. Steiner-Mrazova L. Vrablik M. COQ2 polymorphisms are not associated with increased risk of statin-induced myalgia/myopathy in the Czech population. Drug Metab. Pers. Ther. 2017 32 4 177 182 10.1515/dmpt‑2017‑0027 29257754
    [Google Scholar]
  37. Isackson P.J. Ochs-Balcom H.M. Ma C. Harley J.B. Peltier W. Tarnopolsky M. Sripathi N. Wortmann R.L. Simmons Z. Wilson J.D. Smith S.A. Barboi A. Fine E. Baer A. Baker S. Kaufman K. Cobb B. Kilpatrick J.R. Vladutiu G.D. Association of common variants in the human eyes shut ortholog (EYS) with statin‐induced myopathy: Evidence for additional functions of EYS. Muscle Nerve 2011 44 4 531 538 10.1002/mus.22115 21826682
    [Google Scholar]
  38. Khine H. Yuet W.C. Adams-Huet B. Ahmad Z. Statin-associated muscle symptoms and SLCO1B1 rs4149056 genotype in patients with familial hypercholesterolemia. Am. Heart J. 2016 179 1 9 10.1016/j.ahj.2016.05.015 27595674
    [Google Scholar]
  39. Linde R. Peng L. Desai M. Feldman D. The role of vitamin D and SLCO1B1 gene polymorphism in statin-associated myalgias. Dermatoendocrinol 2010 2 2 77 84 10.4161/derm.2.2.13509 21547103
    [Google Scholar]
  40. Liu J.E. Liu X.Y. Chen S. Zhang Y. Cai L.Y. Yang M. Lai W.H. Ren B. Zhong S.L. SLCO1B1 521T > C polymorphism associated with rosuvastatin-induced myotoxicity in Chinese coronary artery disease patients: a nested case-control study. Eur. J. Clin. Pharmacol. 2017 73 11 1409 1416 10.1007/s00228‑017‑2318‑z 28812116
    [Google Scholar]
  41. Lu B. Sun L. Seraydarian M. Hoffmann T.J. Medina M.W. Risch N. Iribarren C. Krauss R.M. Oni-Orisan A. Effect of SLCO1B1 T521C on statin‐related myotoxicity with use of lovastatin and atorvastatin. Clin. Pharmacol. Ther. 2021 110 3 733 740 10.1002/cpt.2337 34114646
    [Google Scholar]
  42. Luzum J.A. Kitzmiller J.P. Isackson P.J. Ma C. Medina M.W. Dauki A.M. Mikulik E.B. Ochs-Balcom H.M. Vladutiu G.D. GATM polymorphism associated with the risk for statin-induced myopathy does not replicate in case-control analysis of 715 dyslipidemic individuals. Cell Metab. 2015 21 4 622 627 10.1016/j.cmet.2015.03.003 25863251
    [Google Scholar]
  43. Mangravite L.M. Engelhardt B.E. Medina M.W. Smith J.D. Brown C.D. Chasman D.I. Mecham B.H. Howie B. Shim H. Naidoo D. Feng Q. Rieder M.J. Chen Y.D.I. Rotter J.I. Ridker P.M. Hopewell J.C. Parish S. Armitage J. Collins R. Wilke R.A. Nickerson D.A. Stephens M. Krauss R.M. A statin-dependent QTL for GATM expression is associated with statin-induced myopathy. Nature 2013 502 7471 377 380 10.1038/nature12508 23995691
    [Google Scholar]
  44. Marciante K.D. Durda J.P. Heckbert S.R. Lumley T. Rice K. McKnight B. Totah R.A. Tamraz B. Kroetz D.L. Fukushima H. Kaspera R. Bis J.C. Glazer N.L. Li G. Austin T.R. Taylor K.D. Rotter J.I. Jaquish C.E. Kwok P.Y. Tracy R.P. Psaty B.M. Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenet. Genomics 2011 21 5 280 288 10.1097/FPC.0b013e328343dd7d 21386754
    [Google Scholar]
  45. Oh J. Ban M.R. Miskie B.A. Pollex R.L. Hegele R.A. Genetic determinants of statin intolerance. Lipids Health Dis. 2007 6 1 7 10.1186/1476‑511X‑6‑7 17376224
    [Google Scholar]
  46. Ovesjö M.L. Skilving I. Bergman P. Rane A. Ekström L. Björkhem-Bergman L. Low vitamin D levels and genetic polymorphism in the vitamin D receptor are associated with increased risk of statin‐induced myopathy. Basic Clin. Pharmacol. Toxicol. 2016 118 3 214 218 10.1111/bcpt.12482 26423691
    [Google Scholar]
  47. Ramakumari N Indumathi B Katkam SK Kutala VK Impact of pharmacogenetics on statin-induced myopathy in South-Indian subjects Indian Heart J 2018 70 Suppl 3 S120 S125 10.1016/j.ihj.2018.07.009
    [Google Scholar]
  48. Ruaño G. Thompson P.D. Windemuth A. Seip R.L. Dande A. Sorokin A. Kocherla M. Smith A. Holford T.R. Wu A.H.B. Physiogenomic association of statin‐related myalgia to serotonin receptors. Muscle Nerve 2007 36 3 329 335 10.1002/mus.20871 17600820
    [Google Scholar]
  49. Link E. Parish S. Armitage J. Bowman L. Heath S. Matsuda F. Gut I. Lathrop M. Collins R. SLCO1B1 variants and statin-induced myopathy--A genomewide study. N. Engl. J. Med. 2008 359 8 789 799 10.1056/NEJMoa0801936 18650507
    [Google Scholar]
  50. Shahrure Z.M. Irshaid Y.M. Mustafa K.N. Abujbara M.A. Al Shhab M. El-Khateeb M.S. Ajlouni K.M. SLCO1B1 gene polymorphisms (rs2306283 and rs4149056) and statin-induced myopathy in Jordanian diabetics. Curr Rev Clin Exp Pharmacol. 2021 16 3 281 288 10.2174/1574884715666200827105612 32860365
    [Google Scholar]
  51. Shek A.B. Kurbanov R.D. Alieva R.B. Abdullaeva G.J. Nagay A.V. Abdullaev A.A. Hoshimov S.U. Nizamov U.I. Personalized rosuvastatin therapy in problem patients with partial statin intolerance. Arch. Med. Sci. Atheroscler. Dis. 2018 3 1 83 89 10.5114/amsad.2018.76826 30775595
    [Google Scholar]
  52. K Siddiqui M. Maroteau C. Veluchamy A. Tornio A. Tavendale R. Carr F. Abelega N.U. Carr D. Bloch K. Hallberg P. Yue Q.Y. Pearson E.R. Colhoun H.M. Morris A.D. Dow E. George J. Pirmohamed M. Ridker P.M. Doney A.S.F. Alfirevic A. Wadelius M. Maitland-van der Zee A.H. Chasman D.I. Palmer C.N.A. A common missense variant of LILRB5 is associated with statin intolerance and myalgia. Eur. Heart J. 2017 38 48 3569 3575 10.1093/eurheartj/ehx467 29020356
    [Google Scholar]
  53. Vladutiu G.D. Isackson P.J. Kaufman K. Harley J.B. Cobb B. Christopher-Stine L. Wortmann R.L. Genetic risk for malignant hyperthermia in non-anesthesia-induced myopathies. Mol. Genet. Metab. 2011 104 1-2 167 173 10.1016/j.ymgme.2011.07.001 21795085
    [Google Scholar]
  54. Wilke R.A. Moore J.H. Burmester J.K. Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage. Pharmacogenet. Genomics 2005 15 6 415 421 10.1097/01213011‑200506000‑00007 15900215
    [Google Scholar]
  55. V Willrich M.A. Kaleta E.J. Bryant S.C. Spears G.M. Train L.J. Peterson S.E. Lennon V.A. Kopecky S.L. Baudhuin L.M. Genetic variation in statin intolerance and a possible protective role for UGT1A1. Pharmacogenomics 2018 19 2 83 94 10.2217/pgs‑2017‑0146 29210320
    [Google Scholar]
  56. Zhang L. Lv H. Zhang Q. Wang D. Kang X. Zhang G. Li X. Association of SLCO1B1 and ABCB1 genetic variants with atorvastatin-induced myopathy in patients with acute ischemic stroke. Curr. Pharm. Des. 2019 25 14 1663 1670 10.2174/1381612825666190705204614 31298164
    [Google Scholar]
  57. Zuccaro P. Mombelli G. Calabresi L. Baldassarre D. Palmi I. Sirtori C.R. Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin. Pharmacol. Res. 2007 55 4 310 317 10.1016/j.phrs.2006.12.009 17289397
    [Google Scholar]
  58. Sai K. Kajinami K. Akao H. Iwadare M. Sato-Ishida R. Kawai Y. Takeda K. Tanimoto T. Yamano T. Akasaka T. Ishida T. Hirata K. Saku K. Yagi S. Soeki T. Sata M. Ueno M. Miyazaki S. Shiraki A. Oyama J. Node K. Sugamura K. Ogawa H. Kurose K. Maekawa K. Matsuzawa Y. Imatoh T. Hasegawa R. Saito Y. A possible role for HLA-DRB1*04:06 in statin-related myopathy in Japanese patients. Drug Metab. Pharmacokinet. 2016 31 6 467 470 10.1016/j.dmpk.2016.09.002 27839692
    [Google Scholar]
  59. Kitzmiller J. Mikulik E. Dauki A. Mukherjee C. Luzum J. Pharmacogenomics of statins: Understanding susceptibility to adverse effects. Pharm. Genomics Pers. Med. 2016 9 97 106 10.2147/PGPM.S86013 27757045
    [Google Scholar]
  60. Zheng E. Madura P. Grandos J. Broncel M. Pawlos A. Woźniak E. Gorzelak-Pabiś P. When the same treatment has different response: The role of pharmacogenomics in statin therapy. Biomed. Pharmacother. 2024 170 115966 10.1016/j.biopha.2023.115966 38061135
    [Google Scholar]
  61. Cooper-DeHoff R.M. Niemi M. Ramsey L.B. Luzum J.A. Tarkiainen E.K. Straka R.J. Gong L. Tuteja S. Wilke R.A. Wadelius M. Larson E.A. Roden D.M. Klein T.E. Yee S.W. Krauss R.M. Turner R.M. Palaniappan L. Gaedigk A. Giacomini K.M. Caudle K.E. Voora D. The clinical pharmacogenetics implementation consortium guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and statin‐associated musculoskeletal symptoms. Clin. Pharmacol. Ther. 2022 111 5 1007 1021 10.1002/cpt.2557 35152405
    [Google Scholar]
  62. Grundy S.M. Stone N.J. Bailey A.L. Beam C. Birtcher K.K. Blumenthal R.S. Braun L.T. de Ferranti S. Faiella-Tommasino J. Forman D.E. Goldberg R. Heidenreich P.A. Hlatky M.A. Jones D.W. Lloyd-Jones D. Lopez-Pajares N. Ndumele C.E. Orringer C.E. Peralta C.A. Saseen J.J. Smith S.C. Jr Sperling L. Virani S.S. Yeboah J. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: Executive summary. J. Am. Coll. Cardiol. 2019 73 24 3168 3209 10.1016/j.jacc.2018.11.002 30423391
    [Google Scholar]
/content/journals/crcep/10.2174/0127724328356429250315163111
Loading
Genetic Determinants of Statin-induced Myopathy: A Network Meta-analysis of Observational Studies
Bentham Science Publishers ; https://doi.org/10.2174/0127724328356429250315163111
/content/journals/crcep/10.2174/0127724328356429250315163111
/content/journals/crcep/10.2174/0127724328356429250315163111
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher's website along with the published article.

file format download Download

  • Article Type:     Research Article
Keywords: statin-induced myopathy (SIM) ; meta-analysis ; pharmacogenomics ; SLCO1B1 ; drug transporters

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test